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OBJECTIVE: This prospective study investigated the diagnostic significance of the N-terminal pro-brain
natriuretic (NT-proBNP) and troponin I peptides in emergency department patients presenting with
palpitations.
METHODS: Two groups of patients with palpitations but without documented supraventricular tachycardia
were compared: a group with supraventricular tachycardia (n= 49) and a control group (n=47). Both groups
were diagnosed using electrophysiological studies during the study period. Blood samples were obtained from
all of the patients to determine the NT-proBNP and troponin I levels within the first hour following arrival in
the emergency department.
RESULT: The mean NT-proBNP levels were 207.74¡197.11 in supraventricular tachyarrhythmia group and
39.99¡32.83 pg/mL in control group (p,0.001). To predict supraventricular tachycardia, the optimum NT-proBNP
thresholdwas 61.15 pg/mL, as defined by the receiver operating characteristic (ROC) curve,with a non-significant area
under the ROC curve of 0.920 (95% CI, 0.86-0.97, p,0.001). The NT-proBNP cut-off for diagnosing supraventricular
tachycardia had 81.6% sensitivity and 91.5% specificity. Supraventricular tachycardia was significantly more frequent
in the patients with NT-proBNP levels $61.15 pg/mL (n=44, 90.9%, p.0.001). The mean troponin I levels were
0.17¡0.56 and 0.01¡0.06 pg/mL for the patients with and without supraventricular tachycardia, respectively
(p,0.05). Of the 96 patients, 21 (21.87%) had troponin I levels$0.01: 2 (4.25%) in the control group and 19 (38.77%)
in the supraventricular tachycardia group (p,0.001).
CONCLUSION: Troponin I and, in particular, NT-proBNP peptide were helpful for differentiating supraventricular
tachycardia from non- supraventricular tachycardia palpitations. Further randomized, large, multicenter trials are
needed to define the benefit and diagnostic role of NT-proBNP and troponin I in the management algorithm of
patients presenting with palpitations in emergency departments.
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& INTRODUCTION
Palpitations, a common symptom of patients presenting
to the emergency department, can be linked to serious (but
treatable) cardiac arrhythmias (1). Many patients with this
symptom arrive at the emergency department with or
without documented supraventricular tachyarrhythmia (SVT).
Diagnosing palpitations can be difficult in the emergency
department, and thewaiting period for a first appointmentwith
an arrhythmia clinic can be long. A detailed history, physical
examination, and electrocardiograph are of limited value in the
differential diagnosis because most rhythm disturbances are
paroxysmal in nature; therefore, in many cases, the etiology of
palpitations remains unclear in the emergency department. The
majority of these patients have anxiety or panic disorders (2,3).
The most important problem faced by emergency department
physicians is determining which patients to send to arrhythmia
clinics.
The literature contains only limited data from small-scale
studies assessing the diagnostic values of N-terminal of
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brain natriuretic peptide (NT-proBNP) and troponin I in
patients presenting to the emergency department with
palpitations (4-6). Consequently, this prospective study
investigated the diagnostic significance of the NT-proBNP
and troponin I peptides in emergency department patients
presenting with palpitations.
& SUBJECTS AND METHODS
Study Design and Patients
This prospective cohort study was performed in the ED of
Abant I˙zzet Baysal University, School of Medicine Hospital,
between 2011 and 2012. The study was approved by the
local ethics committee. During the study period, 326
consecutive patients with palpitations were treated in the
emergency department. All of the patients’ baseline electro-
cardiograms (ECGs) were normal. Blood samples were
obtained from all of the patients within the first hour
following arrival in the emergency department. After
providing pre-hospital care, we excluded 175 patients who
met the exclusion criteria described below. A total of 151
patients were directed to the Cardiology Arrhythmia Clinic
to undergo an electrophysiological study. Some of these 151
patients underwent this study based on their 12-lead ECGs,
but some patients were diagnosed based on their histories,
symptoms, and physical examinations. In addition, 55
patients were excluded from the study for other reasons,
including failing to provide informed consent forms (n = 38),
presenting with atrial fibrillation (n= 7), and failing to
undergo an electrophysiological study (n= 10). Ninety-six
patients met the inclusion criteria and were included in the
study. Two patient groups were compared: an SVT group
(n = 49) and a control group (n= 47). During the study
period, both groups were diagnosed using electrophysiol-
ogy studies. The recruitment, exclusion, and subsequent
grouping of all patients are also shown in the flowchart
(Figure 1). We used blood samples from the SVT and control
groups to determine the NT-proBNP and troponin I levels.
Data on baseline demographic characteristics, clinical
history, and clinical signs were gathered by trained research
personnel in the emergency department. Electrocar-
diographs were obtained and interpreted by the attending
physician in the emergency department. The exclusion
criteria were age ,16 years, a history of renal insufficiency,
trauma, severe coronary artery disease, right and/or left
systolic dysfunction, pneumonia, pulmonary embolism,
carcinoma, pneumothorax, pleural effusion, intoxication
(drugs), anaphylactic reactions, asthma exacerbation,
chronic renal failure requiring hemodialysis, diabetes
mellitus, hypertension, atrial fibrillation (paroxysmal or
sustained in both conditions), ventricular tachycardia
(paroxysmal or sustained in both conditions), and other
causes of elevated NT-proBNP and troponin I levels.
Patients with a myocardial infarction or acute renal failure
were also excluded, as these conditions are known to
increase NT-proBNP and troponin I levels.
Measurement of NT-proBNP and Troponin I Levels
Blood samples were obtained from all of the patients to
determine the NT-proBNP and troponin I levels within the
Figure 1 - Recruitment, exclusion, and subsequent grouping of all patients.
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first hour after arriving in the emergency department.
During the initial evaluations, a 5-mL blood sample was
collected in tubes containing potassium ethylenediaminete-
traacetic acid (1 mg/mL blood). The samples were centri-
fuged at 4 C˚, and the plasma was then separated and frozen
at 280 C˚ before analysis. Samples were analyzed using the
Roche NT-proBNP electrochemiluminescent assay, and
testing was performed on an Elecsys 1010 analyzer (Roche
Diagnostics, Mannheim, Germany). The assay precision,
analytical sensitivity, interferences, and stability have all
been described previously (6). The troponin I level was
analyzed in samples using ELISA kits (Roche Diagnostics),
and the results were evaluated according to the manufac-
turer’s instructions (with a 99th percentile cutoff point of
0.1 pg/mL).
Electrophysiological Study Protocol
The patients selected to undergo an electrophysiological
study had already undergone extensive negative workups,
including risk factor analysis, patient history, physical
examination, elimination of postural hypotension or hypo-
glycemia, baseline ECG, carotid sinus massage, 24-h
ambulatory monitoring, and echocardiogram. The electro-
physiological study was performed in the case of either an
absent evident etiology or a clinically suspected cardiac
cause. An echocardiogram and a complete electrophysiolo-
gical study were performed. The electrophysiological study
included measuring the sinus node recovery time, HV
interval at baseline and under stress by incremental pacing,
inducibility of ventricular arrhythmia by programmed
ventricular pacing (with three cycles and three extra
stimuli), and inducibility of supraventricular arrhythmia
using an atrial pacing protocol. The electrophysiological
study results were considered positive with the induction of
a rapid supraventricular arrhythmia with symptoms similar
to the patient-reported symptoms.
Statistical Analysis
The baseline characteristics were reported as counts and
proportions or means ¡ standard deviations, as appro-
priate. Continuous variables were compared between the
groups using nonparametric rank tests (Mann-Whitney U-
test and Kruskal-Wallis test), and qualitative variables were
compared using Pearson’s chi-square test. The diagnostic
value of NT-proBNP was assessed using receiver operating
characteristic (ROC) curve analysis. Logistic regression
models were fitted to calculate the risk (odds ratio [OR]
and 95% confidence interval [CI]) for SVT. All models were
evaluated for interactions, and none were found. p-values
,0.05 were considered statistically significant. The SPSS
ver. 15.0 (SPSS, Chicago, IL) statistical software was used.
& RESULTS
The majority of the patients were female, less than 35
years of age, and presented with a history of more than five
palpitation episodes. The mean patient age was 34¡21
years (71% females, 29% males). The baseline and clinical
characteristics are shown in Table 1.
The mean ¡ SD NT-proBNP levels were 207.74¡197.11
and 39.99¡32.83 pg/mL for the patients with and without
SVT, respectively (p,0.001; Figure 2). To predict SVT, the
optimum NT-proBNP threshold was 61.15 pg/mL, as
defined by the ROC curve, with a significant area under
the ROC curve of 0.920 (95% CI 0.86-0.97, p,0.001; Figure 3).
An NT-proBNP cut-off level $61.15 pg/mL for diagnosing
SVT had 81.6% sensitivity and 91.5% specificity. SVT was
significantly more frequent in the patients with NT-proBNP
levels $61.15 pg/mL (n= 44; 90.9%, p,0.001). The mean ¡
SD troponin I values were 0.17¡0.56 and 0.01¡0.06 pg/mL
for the patients with and without SVT, respectively
(p= 0.018). Of these 96 patients, 21 (4.25%) had troponin I
levels #0.001 pg/mL. Two of these 21 patients (4.25%) were
in the control group, and 19 (38.77%) were in the SVT group
(p,0.001). To predict SVT, the optimum threshold of
Table 1 - Baseline patient characteristics.
SVT group (n=49) Control group (n =47) p-value
Gender (female) 71.4% 65.9% 0.102
Age (years)* 34 (17/54) 33 (18/57) 0.138
Smoking 36.1% 41.2% 0.192
First episode 24.5% 34.9% 0.041
Systolic blood pressure * (mm Hg) 118 (107/127) 116 (109/129) 0.651
Diastolic blood pressure * (mm Hg) 75 (67/86) 73 (66/89) 0.721
Heart rate * (beats per minute) 88 (64/92) 84 (61/95) 0.292
Left ventricular ejection fraction * (%) 62 (58/72) 60 (59/70) 0.271
Left atrial diameter* (mm) 3.0 (2.4/3.3) 2.8 (2.4/3.1) 0.108
NT-proBNP (pg/mL) 207.74¡197.11 39.99¡32.83 , 0.001
Troponin I 0.17¡0.56 0.01¡0.06 0.018
*(median - min/max).
Figure 2 - The mean NT-proBNP levels of the two groups (SVT and
control).
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troponin I was $0.005, as defined by the ROC curve, with a
significant area under the ROC curve of 0.670 (95% CI, 0.56-
0.78, p= 0.004; Figure 2). A troponin I cut-off value $0.005,
which was necessary to diagnose SVT, achieved 38.8%
sensitivity and 95.7% specificity.
A Cox proportional logistic regression hazards analysis,
which was performed to determine the predictive value of
the evaluated parameters (e.g., age, gender, heart rate, mean
diastolic pressure, NT-proBNP level, and troponin level),
showed that NT-proBNP, but not troponin I, was an
independent predictor of SVT (OR 1.130, 95% CI, 0.001-
1596.251, p= 0.000; OR 0.968, 95% CI, 0.951-0.988, p= 0.974,
respectively). The addition of echocardiographic parameters
to the model did not change the results.
In patients with SVT, the NT-proBNP levels were
positively correlated with the heart rate at admission
(r = 0.532, p,0.001), systolic (r = 0.322, p= 0.024) and diastolic
(r = 0.320, p= 0.031) blood pressures, and white blood cell
(WBC) count (r = 0.318, p=0.019). There was no significant
correlation between the NT-proBNP levels and other
laboratory findings (p.0.05). In addition, in patients with
SVT, the troponin I levels were positively correlated only
with the heart rate at admission (r = 0.418, p= 0.021) and
WBC count (r = 0.323, p= 0.031). There was no significant
correlation of the NT-proBNP and troponin I levels with left
atrium size in either group (r = 0.213, r = 0.245, respectively,
p.0.05).
& DISCUSSION
Our study demonstrated that both NT-proBNP and
troponin I assessments can potentially improve the sensi-
tivity of the clinician’s evaluation of patients presenting to
the emergency department with palpitations. In addition,
we showed that a NT-proBNP level .61.15 pg/mL was an
independent predictor of SVT.
Palpitations are defined as sensations of a rapid or
irregular heartbeat (7). Many patients with palpitations
have anxiety or panic disorders. Studies have shown that
the prevalence of panic disorder in patients with palpita-
tions is 15-31% (8,9). However, palpitations can also be
linked to serious, although treatable, cardiac arrhythmias
(1). In previous studies, 50% of palpitation cases were traced
to cardiac causes (10,11). Diagnosing palpitations can be
difficult in the emergency department, and the wait time for
a first appointment at an arrhythmia clinic can be long. An
important problem faced by emergency department physi-
cians involves determining which patients to refer to
arrhythmia clinics. If a cause can be determined in the
initial clinical assessment, management decisions are
relatively straightforward. In addition, another important
problem is that palpitation symptoms recur frequently. A
detailed history, physical examination, and ECG can aid the
differential diagnosis because most rhythm disturbances are
paroxysmal in nature. An ECG obtained during a palpita-
tion episode is the reference standard, but obtaining a
valuable ECG is usually impossible (12). Consequently, in
many cases, the etiology of palpitations remains unclear in
the emergency department. We found that NT-proBNP and
troponin I provided important diagnostic information that
is useful in the early evaluation of palpitations in emergency
departments.
Natriuretic peptides (BNP and NT-pro-BNP) are markers
of myocardial wall stress and have been used as markers for
some types of heart disease (13). Previous studies have
concluded that a rapid heart rate resulted from stimulation
by natriuretic peptides. Schiebinger et al. showed that
increased atrial stimulation from 120-240 beats per minute
led to a significant increase in atrial natriuretic peptide
secretion in isolated rat hearts (14). Qi et al. observed a
significant increase in BNP associated with various tachy-
cardias in an experimental animal study (15). Some studies
have shown that natriuretic peptide is increased in plasma
during acute attacks of paroxysmal supraventricular tachy-
cardia and falls rapidly after reversion to sinus rhythm
(16,17). These studies concluded that stimulation of
natriuretic peptide secretion may be responsible for the
polyuria and natriuresis associated with SVT. Pecini et al.
found a significant increase in atrial and brain natriuretic
peptides during atrioventricular nodal reentry tachycardia
in peripheral venous blood (18). In another interesting
study, Brueckmann et al. determined the time course of NT-
proANP levels in patients undergoing radiofrequency
catheter ablation for paroxysmal supraventricular tachycar-
dias (19). They observed that NT-proANP levels increased
in patients presenting with paroxysmal supraventricular
tachycardias and decreased shortly after RF catheter
ablation, possibly reflecting a transient reduction in ANP
secretion from injured myocardial cells. They concluded
that lower NT-proANP levels may serve as a useful
laboratory marker with which to determine the long-term
success of radiofrequency ablation. Previous studies have
shown that NT-proBNP was more sensitive compared with
BNP and had an advantage in detecting patients with mild
or asymptomatic heart disease because of its longer half-life
(20,21). Consistent with these studies, we also preferred
NT-proBNP over troponin I as a diagnostic marker.
Additionally, we observed that NT-proBNP could be used
Figure 3 - ROC curve analysis of NT-proBNP and troponin I.
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as a diagnostic marker with which to identify supraven-
tricular tachycardia patients in the emergency department.
A NT-proBNP cut-off $61.15 pg/mL to diagnose SVT
achieved 81.6% sensitivity and 91.5% specificity. In addi-
tion, only NT-proBNP was an independent predictor of SVT
in this study.
Similar to our results, there have been a few reports of
troponin elevation in patients with various tachyarrhyth-
mias (5,6,22). Kanjwal et al. identified patients with
supraventricular tachycardia who had elevated troponin
levels without evidence of coronary artery disease (23). All
of these patients had elevated troponin I levels and
underwent coronary angiography that revealed normal
epicardial coronary arteries. In the present study, we
observed that the mean troponin I values were significantly
higher in the SVT patients compared with the controls. In
addition, we excluded patients with coronary artery disease
or acute renal failure, as these conditions are known to
increase NT-proBNP and troponin I levels (22,23).
Our study showed the significant prognostic value of NT-
proBNP and troponin I for diagnosing palpitations in the
emergency department. We believe that the exact mechan-
ism for these elevations may be the shortening of diastole
with subsequent subendocardial ischemia. Coronary perfu-
sion, particularly to the subendocardium, occurs predomi-
nantly during the diastole phase (21). In SVT, the increase in
heart rate causes diastole to shorten, with a significant
decrease in subendocardial perfusion.
Some limitations of this study should be discussed. First,
the main limitation of our study was its relatively small
population. This study was performed over a one-year
period. Because a small sample size results in low statistical
power for equivalency testing, negative results may be
simply due to chance. Second, our study had a single-center
prospective design. Future prospective studies at larger
multicenters are required to confirm our results. The other
limitation is that we cannot apply our results to the general
population because of the broad exclusion criteria.
To our knowledge, this is the first report of a marker (NT-
proBNP and troponin I) strategy aimed at diagnosing SVT
based on common palpitations.We have shown that the routine
evaluation of NT-proBNP and troponin I may be used to
identify supraventricular tachycardia patients in the ED. The
results of this study require validation in large, multicenter
studies prior to the incorporation of NT-proBNP and troponin I
as diagnostic markers in the clinical arena.
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